Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Hypertension Receiving Bevacizumab for Breast Cancer

This genetic research study is using whole exome sequencing — a test that reads nearly all the protein-coding parts of a person's DNA — to try to identify inherited genetic variants that may explain why some breast cancer patients develop severe high blood pressure as a side effect when treated with the drug bevacizumab. **You may be eligible if...** - You are of European American ancestry and have DNA samples available - You are designated as either a case (you developed Grade 3 or 4 high blood pressure as a side effect of bevacizumab treatment) or a control (you completed a full course of bevacizumab without developing high blood pressure) **You may NOT be eligible if...** - You do not meet the above criteria Talk to your doctor to see if this trial is right for you.